今日药学

调节性T细胞在自身免疫性疾病中的研究进展

PDF下载

秦筱津 ¹^,² , 代彩玲 ² , 温玉莹 ² , 马雪百合 ² , 段小群 ¹^,^* , 杨威 ¹^,²^,^*

今日药学 | 药学进展 2026,36(7): 545-552

收起

今日药学 |药学进展 2026 , 36 (7) : 545 -552

调节性T细胞在自身免疫性疾病中的研究进展

全屏

秦筱津¹^,², 代彩玲², 温玉莹², 马雪百合², 段小群¹^,^*, 杨威¹^,²^,^*

作者信息

^1.桂林医科大学药学院，广西　桂林　541199

^2.广州湾区生物医药研究院，广东莱恩医药研究院有限公司，广东省药物非临床评价与研究重点实验室，国家中药现代化工程技术研究中心中药非临床评价分中心，广东省创新药物评价与研究工程技术研究中心，从化区抗感染药物研究与评价工程技术研究中心，广东　广州　510990

通讯作者:

杨威，教授级高级工程师/博士、博士后导师，研究方向：药理毒理，E-mail：yangwei0719@163.com

段小群，教授，博士生导师，研究方向：药理学，E-mail：robortduan@163.com

作者简介:

秦筱津，在读硕士研究生

Research Progress of Regulatory T Cells in Autoimmune Diseases

Xiaojin QIN¹^,², Cailing DAI², Yuying WEN², Baihe MAXUE², Xiaoqun Duan¹^,^*, Wei YANG¹^,²^,^*

Affiliations

^1.School of Pharmacy, Guilin Medical University, Guilin, Guangxi 541199, China

^2.Guangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Non-clinical Evaluation Sub-center for Traditional Chinese Medicine of National Engineering Research Center for Modernization of Traditional Chinese Medicine, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Conghua District Anti-infective Drug Research and Evaluation Engineering and Technology Research Center, Guangzhou, Guangdong 510990, China

出版时间: 2026-07-25 doi: 10.12048/j.issn.1674-229X.2026.07.010

文章导航

摘要

收起

自身免疫性疾病是一类因机体免疫系统错误地将自身健康细胞和组织视为威胁并发起攻击，从而导致持续性炎症反应和组织损伤的疾病，属于当前医学领域中复杂且多样的难题。调节性T细胞（Regulatory T cells，Tregs）是免疫系统中免疫耐受和体内平衡的重要维持者，在免疫疾病中发挥着重要作用。本文围绕Tregs疗法的基础研究和临床进展，探讨其潜在应用价值，重点阐述Tregs的生物学特征及其在自身免疫性疾病中的调控机制，为免疫疗法的发展提供理论依据。

关键词

自身免疫性疾病 / 调节性T细胞 / 调控机制 / 调节性T细胞疗法

Abstract

收起

Autoimmune diseases constitute a complex and diverse challenge in modern medicine，it is manifested that the body′s immune system mistakenly recognizes its own healthy cells and tissues as threats and launches attacks，resulting in persistent inflammatory responses and tissue injury. Regulatory T cells (Tregs) are critical mediators in maintaining immune tolerance and immune homeostasis，and exert vital functions in autoimmune diseases. This paper reviews the basic research and clinical advances in Tregs therapy and discusses its potential application value. It elaborates on the biological characteristics of Tregs and their regulatory mechanism in autoimmune diseases，providing a theoretical basis for the development of immunotherapy.

Key words

autoimmune diseases / regulatory T cells / regulatory mechanism / regulatory T cell therapy

引用本文

秦筱津, 代彩玲, 温玉莹, 马雪百合, 段小群, 杨威. 调节性T细胞在自身免疫性疾病中的研究进展. 今日药学, 2026 , 36 (7) : 545 -552 . DOI: 10.12048/j.issn.1674-229X.2026.07.010

Xiaojin QIN, Cailing DAI, Yuying WEN, Baihe MAXUE, Xiaoqun Duan, Wei YANG. Research Progress of Regulatory T Cells in Autoimmune Diseases[J]. Pharmacy Today, 2026 , 36 (7) : 545 -552 . DOI: 10.12048/j.issn.1674-229X.2026.07.010

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

Biscetti L, De Vanna G, Cresta E, et al. Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms[J]. J Neuroinflammation, 2021, 18(1): 259.

[2]

Cheng Y X, Zhao Y H, Zheng Y. Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity[J]. Chin Med, 2021, 16(1): 114.

[3]

Moingeon P. Artificial intelligence-driven drug development against autoimmune diseases[J]. Trends Pharmacol Sci, 2023, 44(7): 411-424.

[4]

Conrad N, Misra S, Verbakel J Y, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK[J]. Lancet, 2023, 401(10391): 1878-1890.

[5]

Cao F, Liu Y C, Ni Q Y, et al. Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019[J]. Autoimmun Rev, 2023, 22(8): 103359.

[6]

Raffin C, Vo L T, Bluestone J A. Treg cell-based therapies: challenges and perspectives[J]. Nat Rev Immunol, 2020, 20(3): 158-172.

[7]

Sakaguchi S, Mikami N, Wing J B, et al. Regulatory T cells and human disease[J]. Annu Rev Immunol, 2020, 38: 541-566.

[8]

Dominguez-Villar M, Hafler D A. Regulatory T cells in autoimmune disease[J]. Nat Immunol, 2018, 19(7): 665-673.

[9]

Lourenço E V, La Cava A. Natural regulatory T cells in autoimmunity[J]. Autoimmunity, 2011, 44(1): 33-42.

[10]

黄尚, 朱同玉, 戎瑞明. 诱导调节T细胞的鉴别及生成[J]. 中国临床医学, 2014, 21(1): 98-101.

[11]

陈军浩, 张葵. 天然调节T细胞与诱导调节T细胞的生物学特性[J]. 现代生物医学进展, 2012, 12(2): 389-392.

[12]

Goldmann O, Nwofor O V, Chen Q, et al. Mechanisms underlying immunosuppression by regulatory cells[J]. Front Immunol, 2024, 15: 1328193.

[13]

Sugiyama D, Hinohara K, Nishikawa H. Significance of regulatory T cells in cancer immunology and immunotherapy[J]. Exp Dermatol, 2023, 32(3): 256-263.

[14]

Guan Q D, Gao X L, Wang J H, et al. Cytokines in autoimmune disease[J]. Mediat Inflamm, 2017, 2017: 5089815.

[15]

Lai Y P, Dong C. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases[J]. Int Immunol, 2016, 28(4): 181-188.

[16]

Valentini N, Requejo Cier C J, Lamarche C. Regulatory T-cell dysfunction and its implication for cell therapy[J]. Clin Exp Immunol, 2023, 213(1): 40-49.

[17]

姚曦, 李向培, 倪进东, 等. SLE患者临床表现、自身抗体的相关性分析及其性别、年龄特征调查[J]. 安徽医科大学学报, 2008, 43(1): 75-78.

[18]

Lazar S, Kahlenberg J M. Systemic lupus erythematosus: new diagnostic and therapeutic approaches[J]. Annu Rev Med, 2023, 74: 339-352.

[19]

蔡小燕, 罗敏, 林小军, 等. Th17和Treg细胞在系统性红斑狼疮患者外周血中的表达[J]. 中华医学杂志, 2012, 92(7): 460-463.

[20]

Shan J, Jin H, Xu Y. T cell metabolism: a new perspective on Th17/treg cell imbalance in systemic lupus erythematosus[J]. Front Immunol, 2020, 11: 1027.

[21]

Huang J G, Li X L, Zhu Q M, et al. Imbalance of Th17 cells, Treg cells and associated cytokines in patients with systemic lupus erythematosus: A meta-analysis[J]. Front Immunol, 2024, 15: 1425847.

[22]

Pan L, Lu M P, Wang J H, et al. Immunological pathogenesis and treatment of systemic lupus erythematosus[J]. World J Pediatr, 2020, 16(1): 19-30.

[23]

Graßhoff H, Comdühr S, Monne L R, et al. Low-dose IL-2 therapy in autoimmune and rheumatic diseases[J]. Front Immunol, 2021, 12: 648408.

[24]

Jiang N, Li M T, Zhang H F, et al. Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study[J]. Lupus Sci Med, 2022, 9(1): e000617.

[25]

Gao Y F, Fan X Z, Li R S, et al. Rapamycin relieves lupus nephritis by regulating TIM-3 and CD4⁺CD25⁺Foxp3+ Treg cells in an MRL/lpr mouse model[J]. Cent Eur J Immunol, 2022, 47(3): 206-217.

[26]

Kanno T, Nakajima T, Miyako K, et al. Lipid metabolism in Th17 cell function[J]. Pharmacol Ther, 2023, 245: 108411.

[27]

Zhong W, Feng L H, Tian W, et al. SMURF1 inhibits the Th17 and Th_17.1 polarization and improves the Treg/Th17 imbalance in systemic lupus erythematosus through the ubiquitination of RORγt[J]. Mol Immunol, 2023, 157: 186-194.

[28]

Doglio M, Ugolini A, Bercher-Brayer C, et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus[J]. Nat Commun, 2024, 15: 2542.

[29]

Galassi G, Iori E, Mazzoli M, et al. Recurrency in myasthenic crisis[J]. Acta Neurol Belg, 2024, 124(2): 729-731.

[30]

Huang J Y, Yan Z, Song Y F, et al. Nanodrug delivery systems for myasthenia gravis: advances and perspectives[J]. Pharmaceutics, 2024, 16(5): 651.

[31]

Rao J, Li S, Wang X, et al. Comparison of peripheral blood regulatory T cells and functional subsets between ocular and generalized myasthenia gravis[J]. Frontiers in Medicine, 2022, 9: 851808.

[32]

Xu W H, Zhang A M, Ren M S, et al. Changes of treg-associated molecules on CD4⁺CD25⁺Treg cells in myasthenia gravis and effects of immunosuppressants[J]. J Clin Immunol, 2012, 32(5): 975-983.

[33]

Sun J, Xie Q F, Sun M J, et al. Curcumin protects mice with myasthenia gravis by regulating the gut microbiota, short-chain fatty acids, and the Th17/Treg balance[J]. Heliyon, 2024, 10(4): e26030.

[34]

Wang Z J, Xu J Q, Mo L Q, et al. The application potential of the regulation of tregs function by irisin in the prevention and treatment of immune-related diseases[J]. Drug Des Dev Ther, 2024, 18: 3005-3023.

[35]

Weng S H, Huang L W, Cai B X, et al. Astragaloside IV ameliorates experimental autoimmune myasthenia gravis by regulating CD4 + T cells and altering gut microbiota[J]. Chin Med, 2023, 18(1): 97.

[36]

Meng Q F, Zhang X X, Zhang Z, et al. Therapeutic potential of artesunate in experimental autoimmune myasthenia gravis by upregulated T regulatory cells and regulation of Th1/Th2 cytokines[J]. Pharmazie, 2018, 73(9): 526.

[37]

Rezaei Kahmini F, Shahgaldi S, Azimi M, et al. Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis: New insights and challenges[J]. Int Immunopharmacol, 2022, 108: 108858.

[38]

Yamada H. Adaptive immunity in the joint of rheumatoid arthritis[J]. Immunol Med, 2022, 45(1): 1-11.

[39]

Jiang Q, Yang G C, Liu Q, et al. Function and role of regulatory T cells in rheumatoid arthritis[J]. Front Immunol, 2021, 12: 626193.

[40]

Li N, Yi Y K, Zhao J, et al. Kaempferol improved rheumatoid arthritis by regulating the immune imbalance of treg/Th17[J]. Curr Med Sci, 2024, 44(6): 1259-1269.

[41]

Sun J X, Li L, Li L Y, et al. Metallothionein-1 suppresses rheumatoid arthritis pathogenesis by shifting the Th17/Treg balance[J]. Eur J Immunol, 2018, 48(9): 1550-1562.

[42]

Dinesh P, Rasool M. Berberine mitigates IL-21/IL-21R mediated autophagic influx in fibroblast-like synoviocytes and regulates Th17/Treg imbalance in rheumatoid arthritis[J]. Apoptosis, 2019, 24(7): 644-661.

[43]

Zhang S X, Chen H R, Wang J, et al. The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis[J]. Front Immunol, 2024, 15: 1359041.

[44]

Zhang X Y, Miao M, Zhang R J, et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial[J]. Signal Transduct Target Ther, 2022, 7: 67.

[45]

Lazibat I. Multiple sclerosis: New aspects of immunopathogenesis[J]. Acta Clin Croat, 2018, 57(2): 352-361.

[46]

Danikowski K M, Jayaraman S, Prabhakar B S. Regulatory T cells in multiple sclerosis and myasthenia gravis[J]. J Neuroinflammation, 2017, 14(1): 117.

[47]

Verreycken J, Baeten P, Broux B. Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers[J]. Hum Vaccines Immunother, 2022, 18(7): 2153534.

[48]

Calahorra L, Camacho-Toledano C, Serrano-Regal M P, et al. Regulatory cells in multiple sclerosis: from blood to brain[J]. Biomedicines, 2022, 10(2): 335.

[49]

Liu R Z, Du S S, Zhao L L, et al. Autoreactive lymphocytes in multiple sclerosis: pathogenesis and treatment target[J]. Front Immunol, 2022, 13: 996469.

[50]

Ghorbani M M, Farazmandfar T, Abediankenari S, et al. Treatment of EAE mice with treg, G-MDSC and IL-2: a new insight into cell therapy for multiple sclerosis[J]. Immunotherapy, 2022, 14(10): 789-798.

[51]

Frikeche J, David M, Mouska X, et al. MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis[J]. J Neuroinflammation, 2024, 21(1): 268.

[52]

Han X Y, Xu N, Yuan J F, et al. Total flavonoids of Astragalus inhibit activated CD4⁺ T cells and regulate differentiation of Th17/Th1/treg cells in experimental autoimmune encephalomyelitis mice by JAK/STAT and NFκB signaling pathways[J]. Am J Chin Med, 2023, 51(5): 1233-1248.

[53]

Zhu H R, Li G L, Yin J, et al. Anlotinib attenuates experimental autoimmune encephalomyelitis mice model of multiple sclerosis via modulating the differentiation of Th17 and Treg cells[J]. Immunopharmacol Immunotoxicol, 2022, 44(4): 594-602.

[54]

Shi C D, Zhang J, Wang H J, et al. Trojan horse nanocapsule enabled in situ modulation of the phenotypic conversion of Th17 cells to Treg cells for the treatment of multiple sclerosis in mice[J]. Adv Mater, 2023, 35(11): 2210262.

[55]

Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus[J]. Nat Rev Dis Primers, 2017, 3: 17016.

[56]

Serr I, Drost F, Schubert B, et al. Antigen-specific treg therapy in type 1 diabetes-challenges and opportunities[J]. Front Immunol, 2021, 12: 712870.

[57]

ElEssawy B, Li X C. Type 1 diabetes and T regulatory cells[J]. Pharmacol Res, 2015, 98: 22-30.

[58]

Chistiakov D A, Voronova N V, Chistiakov P A. The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies[J]. Immunol Lett, 2008, 118(1): 1-5.

[59]

Rojas M, Heuer L S, Zhang W C, et al. The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes[J]. Front Immunol, 2022, 13: 918837.

[60]

Hefazi M, Bolivar-Wagers S, Blazar B R. Regulatory T cell therapy of graft-versus-host disease: advances and challenges[J]. Int J Mol Sci, 2021, 22(18): 9676.

[61]

Reading J L, Roobrouck V D, Hull C M, et al. Augmented expansion of Treg cells from healthy and autoimmune subjects via adult progenitor cell co-culture[J]. Front Immunol, 2021, 12: 716606.

[62]

Fritsche E, Volk H D, Reinke P, et al. Toward an optimized process for clinical manufacturing of CAR-treg cell therapy[J]. Trends Biotechnol, 2020, 38(10): 1099-1112.

[63]

Cortez J T, Montauti E, Shifrut E, et al. CRISPR screen in regulatory T cells reveals modulators of Foxp3[J]. Nature, 2020, 582(7812): 416-420.

[64]

Wegrzyn A S, Kedzierska A E, Obojski A. Identification and classification of distinct surface markers of T regulatory cells[J]. Front Immunol, 2023, 13: 1055805.

[65]

Hippen K L, Hefazi M, Larson J H, et al. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease[J]. Front Immunol, 2022, 13: 926550.

[66]

Rana J, Biswas M. Regulatory T cell therapy: current and future design perspectives[J]. Cell Immunol, 2020, 356: 104193.

2026年第36卷第7期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.12048/j.issn.1674-229X.2026.07.010

接收时间：2025-12-16
首发时间：2026-10-27
出版时间：2026-07-25

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-12-16

基金

作者信息

^1.桂林医科大学药学院，广西　桂林　541199

通讯作者:

杨威，教授级高级工程师/博士、博士后导师，研究方向：药理毒理，E-mail：yangwei0719@163.com

段小群，教授，博士生导师，研究方向：药理学，E-mail：robortduan@163.com

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/jryx/CN/10.12048/j.issn.1674-229X.2026.07.010

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT